October 18-20 | Long Beach, CA

ASCP 2023 Annual Meeting

Engage – Educate – Empower

Thank you for attending!

On-demand recordings now available

Purchase or add access to 90+ on-demand session recordings

Get On-Demand Today

Access all on-demand recorded sessions here

Browse The Schedule

The ASCP 2024 Annual Meeting, being held on September 4-6, 2024, at the Hyatt Regency Chicago, is the essential global gathering of the entire pathology and laboratory medicine community. It is an unequaled experience with education and networking opportunities that will help to bring your skills and knowledge to an entirely new level.

Register early for the best available rates, up to 58% off

Chicago Hyatt Regency

Keynote Speakers


  • Rob Lowe
  • Rob Lowe

    Cancer Patient Advocate Keynote Speaker

    Wednesday, October 18

    Hollywood icon and philanthropist Rob Lowe has been leveraging his platform to stand up to cancer for decades. A passionate advocate for resilience in the face of adversity, the New York Times bestselling author delivers an inspirational message about the fight against cancer from a deeply personal perspective. When he lost three loved ones to breast cancer – his mother, grandmother, and great-grandmother – and his father survived non-Hodgkin's lymphoma, the award-winning actor knew he had to get involved and take a stand against cancer – becoming the first-ever spokesman for breast cancer.

    A devoted advocate, Rob has talked with groups of all kinds about his experiences with the disease, his victories from the work he has been involved with in the fight against cancer, and the importance of continued work by everyone to support cancer survivors.

  • Kizzmekia S. Corbett-Helaire, PhD
  • Kizzmekia S. Corbett-Helaire, PhD

    Scientific Keynote Speaker

    Thursday, October 19

    Dr. Kizzmekia Corbett-Helaire was the scientific lead of the Vaccine Research Center’s coronavirus team at the U.S. National Institutes of Health where she studied coronavirus biology and vaccine development. Those 6 years of research led to the groundbreaking discovery that a stabilized version of a spike protein, which is found on the surface of all coronaviruses, would be a key target for vaccines, treatments, and diagnostics.

    At the onset of the COVID-19 pandemic, she and her colleagues were central to the development of the Moderna mRNA vaccine and the Eli Lilly therapeutic monoclonal antibody, both of which were first to enter clinical trials in the world. As a result, her work is having a substantial impact on ending the worst respiratory-disease pandemic in more than 100 years. Dr. Corbett-Helaire is now an assistant professor in the Department of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health. Her work now extends beyond the rapid development of COVID-19 vaccines to the outlook of this pandemic and future viral pandemics.

Get the On-Demand Package Today

Unlock Access to the On-Demand Package Now

Pathologists Laboratory Professionals Residents
$300 $200 $80